.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

BCMA as a Target in Heavily Pre-Treated RRMM

EP. 1: Treatment Approach for R/R Multiple Myeloma

December 18th 2020

EP. 2: The Rationale for Targeting BCMA in Multiple Myeloma

December 18th 2020

EP. 3: DREAMM-2 Trial Efficacy Data and Recent FDA Approval

January 18th 2021

EP. 4: DREAMM-2 Trial Regimen Safety Profile

January 18th 2021

EP. 5: Management of Ocular Events From DREAMM-2 Regimen

January 25th 2021

EP. 6: DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

January 25th 2021

EP. 7: Next Steps for Use of Belantamab in Clinical Practice

February 1st 2021

EP. 8: Ongoing Approaches Toward Targeting BCMA

February 1st 2021

EP. 9: Influencing Factors to Initially Targeting BCMA in MM

February 1st 2021